ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the work reported here, we use the method to profile BcrAbl activity in chronic myeloid leukemia cell lines that have been developed to exhibit growth in the presence of moderate concentrations of the kinase inhibitor drugs imatinib, nilotinib and dasatinib, and examine the relationships between BcrAbl kinase activity and cell growth in the presence of each inhibitor.